| Literature DB >> 1832625 |
Abstract
This review details the characteristic features of three new progestogens which soon will be available in low-dose combination oral contraceptive agents in the United States. Available data suggest that desogestrel, gestodene, and norgestimate are extremely potent progestogens with few androgenic side effects. The smaller changes in lipids induced by these progestogens seem to confer some advantage to the use of preparations containing one of these agents. Whether this advantage is also present clinically remains to be determined.Entities:
Keywords: Biology; Blood Coagulation Effects; Carbohydrate Metabolic Effects; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--pharmacodynamics; Contraceptive Mode Of Action; Desogestrel--pharmacodynamics; Family Planning; Gestodene--pharmacodynamics; Hematological Effects; Hemic System; Lipid Metabolic Effects; Lipids; Metabolic Effects; Norgestimate--pharmacodynamics; Oral Contraceptives, Combined--pharmacodynamics; Oral Contraceptives--pharmacodynamics; Ovulation Suppression; Physiology
Mesh：
Substances：
Year: 1991 PMID： 1832625 DOI： 10.1016/0010-7824(91)90101-k
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375